A detailed history of Tower Research Capital LLC (Trc) transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 3,671 shares of XERS stock, worth $12,481. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,671
Previous 25,594 85.66%
Holding current value
$12,481
Previous $57,000 82.46%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.06 - $2.96 $45,161 - $64,892
-21,923 Reduced 85.66%
3,671 $10,000
Q2 2024

Aug 13, 2024

BUY
$1.7 - $2.45 $39,844 - $57,423
23,438 Added 1087.11%
25,594 $57,000
Q1 2024

May 15, 2024

SELL
$2.04 - $3.22 $52,411 - $82,728
-25,692 Reduced 92.26%
2,156 $4,000
Q4 2023

Feb 13, 2024

BUY
$1.47 - $2.36 $14,307 - $22,969
9,733 Added 53.73%
27,848 $65,000
Q3 2023

Nov 14, 2023

BUY
$1.8 - $2.69 $24,638 - $36,820
13,688 Added 309.19%
18,115 $33,000
Q2 2023

Aug 14, 2023

SELL
$1.82 - $2.98 $8,251 - $13,511
-4,534 Reduced 50.6%
4,427 $11,000
Q1 2023

May 09, 2023

SELL
$1.03 - $1.63 $10,203 - $16,146
-9,906 Reduced 52.5%
8,961 $14,000
Q4 2022

Feb 10, 2023

SELL
$1.14 - $1.65 $61,548 - $89,083
-53,990 Reduced 74.1%
18,867 $25,000
Q3 2022

Nov 10, 2022

BUY
$1.37 - $1.93 $56,050 - $78,962
40,913 Added 128.08%
72,857 $114,000
Q2 2022

Aug 15, 2022

BUY
$1.48 - $2.64 $22,888 - $40,827
15,465 Added 93.85%
31,944 $49,000
Q1 2022

May 12, 2022

BUY
$2.0 - $2.87 $14,158 - $20,316
7,079 Added 75.31%
16,479 $42,000
Q4 2021

Feb 14, 2022

BUY
$1.8 - $2.93 $16,920 - $27,542
9,400 New
9,400 $28,000

Others Institutions Holding XERS

About Xeris Biopharma Holdings, Inc.


  • Ticker XERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,956,992
  • Market Cap $462M
  • Description
  • Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...
More about XERS
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.